Résumé
PrEP has been an HIV preventive treatment since 2016. Initially of exclusive hospital first-time prescription, PrEP can be introduced by general practitioners since April 2021 after several months of decline in prescription due to the global pandemic. The main objective is to evaluate the proportion and profile of general practitioners who have already initiated PrEP in the Montpellier-Nîmes academy since the authorization of its opening to primary prescription. The secondary objective is to evaluate the barriers to primary prescription. Material and method: this is a quantitative, descriptive and analytical study questioning general practitioners in the former Languedoc-Roussillon region. The Chi2 test and Fisher's test were used to compare the groups of prescribers and non-prescribers, first-time prescribers and physicians renewing PrEP only.Results: between October 2022 and February 2023, 138 physicians were included. 32.6% of physicians had previously prescribed PrEP and 18.1% of physicians had initiated it. Physicians prescribing PrEP were more frequently practicing in urban areas, close to a CeGIDD and had more often received training in sexual health. The main obstacles to first-time prescribing were lack of training, fear of an increase in the number of STIs, and fear of less STI screening. A large majority of the responding physicians requested sexual health training. Conclusion: the prescription of PrEP remains centered in urban areas but is tending to be decentralized and democratized. The majority of the obstacles to its prescription are related to a lack of training, which the physicians requested.